Carroll Financial Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | $298K | Sell |
3,408
-50
| -1% | -$4.15K | 0.02% | 323 |
|
|
2021
Q3 | $282K | Sell |
3,458
-560
| -14% | -$50.4K | 0.02% | 331 |
|
|
2021
Q2 | $366K | Sell |
4,018
-138
| -3% | -$12.3K | 0.02% | 295 |
|
|
2021
Q1 | $355K | Buy |
4,156
+128
| +3% | +$11.5K | 0.02% | 287 |
|
|
2020
Q4 | $380K | Sell |
4,028
-194
| -5% | -$17K | 0.03% | 269 |
|
|
2020
Q3 | $367K | Sell |
4,222
-789
| -16% | -$68.4K | 0.03% | 258 |
|
|
2020
Q2 | $437K | Buy |
5,011
+843
| +20% | +$72.8K | 0.04% | 237 |
|
|
2020
Q1 | $343K | Sell |
4,168
-1,156
| -22% | -$103K | 0.03% | 239 |
|
|
2019
Q4 | $504K | Buy |
5,324
+784
| +17% | +$70.3K | 0.04% | 212 |
|
|
2019
Q3 | $394K | Sell |
4,540
-204
| -4% | -$18.3K | 0.03% | 245 |
|
|
2019
Q2 | $433K | Sell |
4,744
-4,531
| -49% | -$383K | 0.04% | 233 |
|
|
2019
Q1 | $799K | Buy |
9,275
+3,963
| +75% | +$318K | 0.07% | 142 |
|
|
2018
Q4 | $404K | Buy |
5,312
+166
| +3% | +$12.9K | 0.05% | 179 |
|
|
2018
Q3 | $397K | Hold |
5,146
| – | – | 0.04% | 200 |
|
|
2018
Q2 | $348K | Buy |
5,146
+163
| +3% | +$11.2K | 0.04% | 210 |
|
|
2018
Q1 | $360K | Buy |
4,983
+412
| +9% | +$31.4K | 0.04% | 206 |
|
|
2017
Q4 | $343K | Sell |
4,571
-43
| -0.9% | -$3.24K | 0.04% | 212 |
|
|
2017
Q3 | $354K | Buy |
4,614
+205
| +5% | +$15.5K | 0.04% | 200 |
|
|
2017
Q2 | $329K | Sell |
4,409
-453
| -9% | -$32.1K | 0.04% | 212 |
|
|
2017
Q1 | $323K | Sell |
4,862
-181
| -4% | -$12.1K | 0.04% | 202 |
|
|
2016
Q4 | $329K | Sell |
5,043
-168
| -3% | -$10.9K | 0.05% | 182 |
|
|
2016
Q3 | $368K | Buy |
5,211
+81
| +2% | +$5.9K | 0.06% | 168 |
|
|
2016
Q2 | $379K | Buy |
5,130
+56
| +1% | +$3.87K | 0.06% | 163 |
|
|
2016
Q1 | $329K | Buy |
5,074
+260
| +5% | +$17.7K | 0.06% | 169 |
|
|
2015
Q4 | $371K | Buy |
4,814
+112
| +2% | +$8.9K | 0.08% | 146 |
|
|
2015
Q3 | $385K | Buy |
4,702
+1,702
| +57% | +$151K | 0.09% | 137 |
|
|
2015
Q2 | $264K | Buy |
3,000
+871
| +41% | +$79.9K | 0.06% | 165 |
|
|
2015
Q1 | $188K | Buy |
2,129
+72
| +4% | +$6.39K | 0.08% | 138 |
|
|
2014
Q4 | $181K | Sell |
2,057
-832
| -29% | -$69K | 0.12% | 119 |
|
|
2014
Q3 | $240K | Sell |
2,889
-296
| -9% | -$23.9K | 0.07% | 139 |
|
|
2014
Q2 | $258K | Sell |
3,185
-112
| -3% | -$8.81K | 0.07% | 145 |
|
|
2014
Q1 | $251K | Buy |
3,297
+338
| +11% | +$24.6K | 0.08% | 133 |
|
|
2013
Q4 | $213K | Sell |
2,959
-117
| -4% | -$8.13K | 0.08% | 139 |
|
|
2013
Q3 | $211K | Buy |
3,076
+39
| +1% | +$2.58K | 0.08% | 140 |
|
|
2013
Q2 | $192K | Buy |
+3,037
| New | +$198K | 0.09% | 118 |
|
Other funds holding NVS
Carroll Financial Associates's NVS Position: Q4 2021 in Review
Carroll Financial Associates reduced its Novartis (NVS) stake by 1.4% in Q4 2021, selling an estimated $4.15K and leaving 3,408 shares worth $298K. The position accounts for 0.02% of the portfolio, ranked #323.
Carroll Financial Associates first reported a position in NVS in Q2 2013 and has held it in 35 quarters since. The position peaked at $799K in Q1 2019. 1,146 funds tracked by Wall St. Rank hold NVS as of Q4 2021.
- Carroll Financial Associates held 3,408 shares of Novartis worth $298K as of Q4 2021.
- Carroll Financial Associates sold 50 Novartis shares in Q4 2021, an estimated $4.15K.
- Novartis made up 0.02% of Carroll Financial Associates's portfolio in Q4 2021, its #323 holding.
- Carroll Financial Associates first reported a position in Novartis in Q2 2013 and has held it in 35 quarters since.
- Carroll Financial Associates's Novartis position peaked at $799K in Q1 2019.
- 1,146 funds tracked by Wall St. Rank held Novartis as of Q4 2021.
Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.